We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.55 | 1.50 | 1.60 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -4.43 | 2.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/2/2018 10:08 | Pwhite please don't bring anymore bad news to this losing con story. Just lie to me and tell me that pyc will spike by 500% or just buy me some rose tinted glasses. | spacedust | |
23/2/2018 08:42 | Mini tumours grown outside the human body for drug treatment is all over the national news today. It was on the radio and TV. The drugs have 88% and 100% accuracy. Who needs computational models when you can test drugs on the real thing outside the human body. Do you see how fast this science moves. | pwhite73 | |
23/2/2018 07:35 | Stig Agree 100% And all this withouth factoring in the Merck-like 0.5 million contracts in the next months. 10p, then 50p then 1quid then our early retirement | the patient investor | |
23/2/2018 00:30 | The Interims being historic weren't all that important from a numbers point of view as we basically knew what was coming anyway. One very positive thing nobody has mentioned as far as I can see is the cashflow situation. Despite a Headline Operating Loss of £220k the actual cash outflow was only c. £40k on a Revenue base of only £170k i.e. with a Revenue base in the second half of £200k (Merck) + £30k + £70k = £300k we should be looking at a cashflow positive 2nd half? even more so if we get more 'Substantial Non-Dilutive' funding from Government on the Cancer DSS tool | the stigologist | |
22/2/2018 18:46 | True no Lamborghini* | spacedust | |
22/2/2018 18:45 | True Lamborghini but will look to take dividends and go for the smooth rise towards 200p. | spacedust | |
22/2/2018 17:22 | Ok I'll qualify what I said. To say NO PIs are selling would be patently untrue, of course aome PIs are selling but far more are interested in buying at this level than selling. But the excess demand is being met by MM drip feeding unplaced placing shares into the markets. Just look at that huge 400k buy at 11:25 where do think the shares are coming from? Good luck with Centrica but you'll never be able to buy a Lamborghini invested in that company. | pwhite73 | |
22/2/2018 17:16 | I have been pwhite. I'm sticking with main markets. Bought in centrica today after the resultsthis morning. | spacedust | |
22/2/2018 16:10 | Yep We could break 10p easily on a good RNS in a matter of HOURS LARGELY OVERSOLD | the patient investor | |
22/2/2018 14:54 | Only a matter of time before #PYC starts to get its share of this market now its tech is validated and starting the rapid adoption curve by Big Pharma | the stigologist | |
22/2/2018 14:53 | Just a $3bn cancer treatment deal | the stigologist | |
22/2/2018 11:41 | Cheers wossupsa. Nice to see the recovery at IMM | volsung | |
21/2/2018 21:42 | All of it volsung (good call on IMM at 109p btw)? | wossupsa | |
21/2/2018 17:36 | myamay16 re: 1816, don't you know an auto-generated article when you see one? No human has written that it's a template with some figures slotted in. Then at the bottom they want you to pay to read other auto-generated cr$p. | on target | |
21/2/2018 17:29 | Maybe, Maybe one day will be doing this with PYC. Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline Proposed Acquisition of Viralytics Would Add Investigational Oncolytic Immunotherapy, CAVATAK ® , Supporting Merck’s Strategy to Broaden Its Pipeline with the Best Scientific Assets Wednesday, February 21, 2018 4:00 am EST KENILWORTH, N.J. & SYDNEY--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Viralytics Limited (ASX: VLA, OTC: VRACY) today announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics, an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers by way of a scheme of arrangement (Scheme) for AUD 1.75 cash per Viralytics share. The proposed acquisition values the total issued shares in Viralytics at approximately AUD 502 million (USD 394 million). The cash consideration of AUD 1.75 per share represents a premium of 160% to the one month volume weighted average price (VWAP) of Viralytics share hxxp://www.mrknewsro | myamay16 | |
21/2/2018 17:25 | 3rd article by Simply Walls st in as many months about PYC ( they showing some interest here ). Who Owns Physiomics Plc (LON:PYC)? Micheal Lombardo February 21, 2018 In this article, I will take a quick look at Physiomics Plc’s (AIM:PYC) recent ownership structure – an unconventional investing subject, but an important one. When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. Differences in ownership structure of companies can have a profound effect on how management’s incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices. Although this is an important factor for long-term investors, many investors can also be impacted by institutional presence and their high-volume trading. Therefore, it is beneficial for us to examine PYC’s ownership structure in more detail. hxxps://simplywall.s | myamay16 | |
21/2/2018 16:19 | Balls shrinking time. | spacedust | |
21/2/2018 15:28 | Thats what's happened to me with PYC since 2009. And silly me bought in again when I saw JC holdings. I'll stick to BT TLW and national grid. Anything comes of this I'll see it as a bonus | spacedust | |
21/2/2018 15:17 | spacedust Yes shorting AIM stocks is the way to go but as a PI they won't let you do it because its a sure fire way to make money. If they ever let you short a stock that's because they know news or heavy buying is on the way to burn you. You can only make money from a surprise where PIs rush in before MM have enough stock to meet demand. This is what happened to PYC in November 2017.Takeovers, oil and gold finds are the types of shocks to the system where MM cannot react quickly enough. But if you just sit on your hands waiting for news they'll casserole you. | pwhite73 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions